Cargando…
Blinded, Double‐Dummy, Parallel‐Group, Phase 2a Randomized Clinical Trial to Evaluate the Efficacy and Safety of a Highly Selective 5‐Hydroxytryptamine Type 4 Receptor Agonist in Critically Ill Patients With Enteral Feeding Intolerance
BACKGROUND: Delayed gastric emptying is the leading cause of enteral feeding intolerance (EFI) in critical illness. This phase 2a study compared TAK‐954, a selective agonist of 5‐hydroxytryptamine type 4 receptors, with metoclopramide in critically ill patients with EFI (NCT01953081). METHODS: A bli...
Autores principales: | Chapman, Marianne J., Jones, Karen L., Almansa, Cristina, Barnes, Chris N., Nguyen, Deanna, Deane, Adam M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891369/ https://www.ncbi.nlm.nih.gov/pubmed/31990087 http://dx.doi.org/10.1002/jpen.1732 |
Ejemplares similares
-
Nasogastric feeding intolerance in the critically ill
por: OConnor, S, et al.
Publicado: (2011) -
The 5-hydroxytryptamine 4 Receptor Agonist-induced Actions and Enteric Neurogenesis in the Gut
por: Takaki, Miyako, et al.
Publicado: (2014) -
The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial
por: Chapman, Marianne J., et al.
Publicado: (2016) -
The efficacy and safety of itopride in feeding intolerance of critically ill patients receiving enteral nutrition: a randomized, double-blind study
por: Elmokadem, Eman Mohamed, et al.
Publicado: (2021) -
Identification of risk factors for enteral feeding intolerance screening in critically ill patients
por: Xu, Lei, et al.
Publicado: (2017)